drugset / Trial / NCT00151073
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
Phase 2
Completed
28 enrolled
University of Michigan Rogel Cancer Center
Aventis Pharmaceuticals · collabNovartis · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Purpose: The aim of this clinical trail is to evaluate the effectiveness of Zoledronate (Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment of patients with hormone-refractory prostate cancer.
Timeline
- Start
- 2002-04
- Primary completion
- 2005-09
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 70 mg/m2 | — |
| Subject | Zoledronic acid | Other / unclassified | 4 mg | Intravenous |
| Subject | estramustine | Other / unclassified | 280 mg | Oral |